ALDH3A1 has been regarded as a therapeutic target in some cancers, like lung, hepatocellular, and prostate carcinomas, based on the evidence that abnormal levels of aldehyde dehydrogenase (ALDH) activity were expressed in human cancer types [26, 27]. The gene discussed is LDHA; the disease is prostate carcinoma.